505522306 06/12/2019

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT5569111

SUBMISSION TYPE:		NEW ASSIGNMENT	
NATURE OF CONVEYAN	CE:	ASSIGNMENT	
CONVEYING PARTY DA	TA		
		Name	Execution Date
RECKITT BENCKISER L	LC		09/01/2018
RECEIVING PARTY DAT	ГА		
Name:	RB HEAL	TH (US) LLC	
Street Address:	399 INTE	RPACE PARKWAY	
City:	PARSIPPANY		
State/Country:	NEW JEF	RSEY	
Postal Code:	07054		
PROPERTY NUMBERS	Total: 15		
Property Type		Number	
Application Number:	15	471783	
Application Number:	13	879741	
Application Number:	29	390387	
Application Number:	29	390388	
Application Number:	29	390389	
Application Number:	13	880658	
Application Number:	09	338423	
Application Number:	15	133062	
Application Number:	13	021240	
Application Number:	29	508682	
Application Number:	29	528731	
Application Number:	29	540070	
Application Number:	15	763920	
Application Number:	15	549063	
Application Number.		122671	

4048852773

Phone:

Email: ryan.schneider@troutman.com							
Correspondent Name: RYAN SCHNEIDER							
Address Line 1: TROUTMAN SANDERS LLP							
Address Line 2:	600 F	PEACHTREE ST NE STE 3000					
Address Line 4: ATLANTA, GEORGIA 30308							
ATTORNEY DOCKET NUMBER: GEN2075/US							
NAME OF SUBMITTER: RYAN A. SCHNEIDER							
SIGNATURE: /Ryan A. Schneider/							
DATE SIGNED:		06/12/2019					
Total Attachments: 10							
source=Reckitt Benckiser LLC RB	Heal	th (US) LLC.Patent Assignment#page1.tif					
source=Reckitt Benckiser LLC RB	Heal	th (US) LLC.Patent Assignment#page2.tif					
source=Reckitt Benckiser LLC RB	Heal	th (US) LLC.Patent Assignment#page3.tif					
source=Reckitt Benckiser LLC RB Health (US) LLC.Patent Assignment#page4.tif							
source=Reckitt Benckiser LLC RB Health (US) LLC.Patent Assignment#page5.tif							
source=Reckitt Benckiser LLC RB Health (US) LLC.Patent Assignment#page6.tif							
source=Reckitt Benckiser LLC RB	source=Reckitt Benckiser LLC RB Health (US) LLC.Patent Assignment#page7.tif						
source=Reckitt Benckiser LLC RB	Heal	th (US) LLC.Patent Assignment#page8.tif					
source=Reckitt Benckiser LLC RB	Heal	th (US) LLC.Patent Assignment#page9.tif					
source=Reckitt Benckiser LLC RB	Heal	th (US) LLC.Patent Assignment#page10.tif					

Dated September 1, 2018

RECKITT BENCKISER LLC

RB HEALTH (US) LLC

PATENT ASSIGNMENT

PATENT REEL: 049451 FRAME: 0058

Patent Assignment

This Agreement is made on September 1, 2018 between:

- (1) Reckitt Benckiser LLC, a Delaware limited liability company, whose principal office is at 399 Interpace Parkway, Parsippany, New Jersey 07054 (the "Assignor"); and
- (2) RB Health (US) LLC, a Delaware limited liability company, whose principal office is at 399 Interpace Parkway, Parsippany, New Jersey 07054 (the "Assignee").

Whereas:

(A) the Assignor has agreed to assign all of its right, title and interest in and to the Patents to the Assignee on the terms of this Agreement.

It is agreed as follows.

1 Definitions and interpretation

1.1 Definitions

In this Agreement, the following capitalised term shall have the meaning set out below:

"**Patents**" means the patents and applications for patents set out in the Schedule to this Agreement.

1.2 Interpretation

In this Agreement, unless otherwise specified:

- **1.2.1** references to this Agreement shall include any Recitals and the Schedule to it and references to Recitals, Clauses and Schedule are to clauses of, and recitals and the schedule to, this Agreement;
- **1.2.2** references to a statute or statutory provision include that statute or provision as modified, re-enacted or consolidated from time to time;
- **1.2.3** a reference to any English legal term shall, for any jurisdiction other than England, be construed as a reference to the term or concept which most nearly corresponds to it in that jurisdiction;
- 1.2.4 headings shall be ignored in interpreting this Agreement; and
- **1.2.5** the words "including", "include", "in particular", and words of similar effect shall not be deemed to limit the general effect of the words that precede them.

2 Assignment

2.1 In consideration of the sum of US\$10.00, the receipt and sufficiency of which is hereby acknowledged by the Assignor, the Assignor hereby assigns to the Assignee all of its right, title and interest in and to the Patents, including:

- 2.1.1 in respect of each patent application comprised within the Patents, the right to prosecute to grant and obtain any patent or similar protection deriving from, any such application;
- 2.1.2 in respect of any invention disclosed in the Patents, the right to make patent applications, including divisionals, and claim priority from, prosecute to grant and obtain patent or similar protection deriving from, any such invention, anywhere in the world
- **2.1.3** in any patent or patent application derived (whether directly or indirectly) from any patent application from which any Patent was derived (whether directly or indirectly);
- 2.1.4 in all patents and other intellectual property rights that derive priority from, or are based on, the Patents, or any patent deriving from any patent application comprised within the Patents, including any term extensions, divisionals, continuations, continuations-inpart, reissues and extensions; and
- 2.1.5 all rights of action arising or accrued relating to the Patents and any patents deriving from any patent application comprised within the Patents, including the right to take and/or defend proceedings for infringement and/or other causes of action arising from ownership thereof, and the right to seek, recover and retain damages and/or an account of profits and all other remedies for all past, current and/or future infringements thereof.

3 Further Assurance

At the request and cost of the Assignee, the Assignor shall execute such documents and do such acts and things as the Assignee may reasonably require for the purpose of giving the Assignee the full benefit of this Agreement.

4 Invalidity

- **4.1** If any provision in this Agreement shall be held to be illegal, invalid or unenforceable, in whole or in part, the provision shall apply with whatever deletion or modification is necessary so that the provision is legal, valid and enforceable and gives effect to the commercial intention of the parties.
- **4.2** To the extent it is not possible to delete or modify the provision, in whole or in part, under Clause 4.1, then such provision or part of it shall, to the extent that it is illegal, invalid or unenforceable, be deemed not to form part of this Agreement and the legality, validity and enforceability of the remainder of this Agreement shall, subject to any deletion or modification made under Clause 4.1, not be affected.

5 Third party rights

The parties do not confer any rights or remedies under this Agreement upon any person other than the parties and their respective successors and permitted assigns.

6 Whole Agreement

This Agreement contains the whole agreement between the Assignor and the Assignee relating to the subject matter of this Agreement at the date of this Agreement, to the exclusion of any terms implied by law which may be excluded by contract, and supersedes any previous written or oral agreement between the Assignor and the Assignee in relation to the matters dealt with in this Agreement. The Assignee agrees and acknowledges that, in entering into this Agreement, it is not relying on any representation, warranty or undertaking not expressly incorporated into it. Nothing in this Clause 6 excludes or limits any liability for fraud.

7 Counterparts

This Agreement may be entered into in any number of counterparts, all of which taken together shall constitute one and the same instrument. The Assignor and the Assignee may enter into this Agreement by executing any such counterpart.

8 Governing Law and jurisdiction

- **8.1** This Agreement and any non-contractual obligations arising out of or in connection with it shall be governed by the law of the State of Delaware.
- **8.2** Each party irrevocably agrees that the federal and state courts of the State of Delaware are to have exclusive jurisdiction to settle any dispute which may arise out of or in connection with this Agreement and that accordingly any proceedings arising out of or in connection with this Agreement shall be brought in such courts. Each party irrevocably submits to the jurisdiction of such courts and waives any objection to proceedings in any such court on the ground of venue or on the ground that the proceedings have been brought in an inconvenient forum.

[signature page follows]

In witness whereof this Agreement has been entered into on the date stated at the beginning.

SIGNED for and on behalf of

RECKITT BENCKISER LLC: By Print Name: Kut MANAGE Title:

Before witness:

Name:

Address:

Occupation:

ERPICE PKy, Parls ppany, NIT 07054 GAL

SIGNED for and on behalf of

RB HEALTH (US) LLC:

By ----

Before witness:

Name:

Address:

Occupation:

NG A ARNESON 399 INTERPACE PLUY, PARSIPPANY, NJ OTOSY PALALEGAL

Schedule 1 Health Patents and Patent Applications - Reckitt Benckiser LLC

Case reference	Country	Current Status	Filing Date	Application Number	Grant Date	Grant Number

Case reference	Country	Current Status	Filing Date	Application Number	Grant Date	Grant Number

11579P3-US-PCT-w US Granted 11 Jan 2006 11/813739 09 Dec 2008 7462289 12445P3-US-PCT-w US Granted 21 Oct 2011 13/879741 17 Feb 2015 8955719 12450P3-US-PCT-w US Granted 21 Oct 2011 13/880658 19 May 2015 9033193 12573P3-US-PCT-w US Granted 25 May 2012 14/122671 09 May 2017 9642501 12873P3-US-PCT US Granted 13 Feb 2015 15/1757070	Case reference	Country	Current Status	Filing Date	Application Number	Grant Date	Grant Number
12445P3-US-PCT-w US Granted 21 Oct 2011 13/879741 17 Feb 2015 8955719 12450P3-US-PCT-w US Granted 21 Oct 2011 13/880658 19 May 2015 9033193 12573P3-US-PCT-w US Granted 25 May 2012 14/122671 09 May 2017 9642501 12873P3-US-PCT US Pending 17 Oct 2016 15/770710 12887P3-US-PCT US Granted 13 Feb 2015 15/115403 30 Jan 2018 9877484 12959P3-US-PCT US Granted 23 Jun 1999 09/338423 07 Nov 2000 6143285 12984P3-US-PCT US Granted 28 Apr 2000 09/559542 16 Apr 2002 6372252 12163P1-US-REX-2 US Granted 15 Apr 2002 10/121706 18 Oct 2005 6955821 12163P1B-US-CIP-2 US Granted 04 Apr 2003 10/406557 23 Nov 2010 7838032 12163P1B-US-CIP-3 US Granted 15 Apr 2003 10/416574 26 Jul 2011 7985420 <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th>							
12445P3-US-PCT-w US Granted 21 Oct 2011 13/879741 17 Feb 2015 8955719 12450P3-US-PCT-w US Granted 21 Oct 2011 13/880658 19 May 2015 9033193 12573P3-US-PCT-w US Granted 25 May 2012 14/122671 09 May 2017 9642501 12873P3-US-PCT US Pending 17 Oct 2016 15/770710 12887P3-US-PCT US Granted 13 Feb 2015 15/115403 30 Jan 2018 9877484 12959P3-US-PCT US Granted 23 Jun 1999 09/338423 07 Nov 2000 6143285 12984P3-US-PCT US Granted 28 Apr 2000 09/559542 16 Apr 2002 6372252 12163P1-US-REX-2 US Granted 15 Apr 2002 10/121706 18 Oct 2005 6955821 12163P1B-US-CIP-2 US Granted 04 Apr 2003 10/406557 23 Nov 2010 7838032 12163P1B-US-CIP-3 US Granted 15 Apr 2003 10/416574 26 Jul 2011 7985420 <td>11579P3-US-PCT-w</td> <td>US</td> <td>Granted</td> <td>11 Jan 2006</td> <td>11/813739</td> <td>09 Dec 2008</td> <td>7462289</td>	11579P3-US-PCT-w	US	Granted	11 Jan 2006	11/813739	09 Dec 2008	7462289
12450P3-US-PCT-w US Granted 21 Oct 2011 13/880658 19 May 2015 9033193 12573P3-US-PCT-w US Granted 25 May 2012 14/122671 09 May 2017 9642501 12873P3-US-PCT US Pending 17 Oct 2016 15/770710		1					8955719
12573P3-US-PCT-w US Granted 25 May 2012 14/122671 09 May 2017 9642501 12873P3-US-PCT US Pending 17 Oct 2016 15/770710					· · · · · · · · · · · · · · · · · · ·		
12887P3-US-PCT-w US Granted 13 Feb 2015 15/115403 30 Jan 2018 9877484 12959P3-US-PCT US Pending 30 Sep 2016 15/763920							
12959P3-US-PCT US Pending 30 Sep 2016 15/763920 Image: Constraint of the system 12566P3-US-PRI US Granted 23 Jun 1999 09/338423 07 Nov 2000 6143285 12984P3-US-PCT US Pending 24 Feb 2016 15/549063 Image: Constraint of the system 6372252 12163P1-US-PRI US Granted 28 Apr 2000 09/559542 16 Apr 2002 6372252 12163P1-US-REX-2 US Granted 22 Apr 2005 90/007514 16 Jun 2009 6372252 12163P1B-US-CIP US Granted 15 Apr 2002 10/121706 18 Oct 2005 6955821 12163P1B-US-CIP-2 US Granted 04 Apr 2003 10/406557 23 Nov 2010 7838032 12163P1B-US-CIP-3 US Granted 15 Apr 2003 10/413530 06 Sep 2011 8012504 12163P1B-US-CIP-4 US Granted 12 Apr 2003 11/158012 26 Jul 2011 7985421 12163P1B-US-CN-7 US Granted 22 Jun 2005 11/158012 26 Jul	12873P3-US-PCT	US	Pending	17 Oct 2016	15/770710		
12566P3-US-PRIUSGranted23 Jun 199909/33842307 Nov 2000614328512984P3-US-PCTUSPending24 Feb 201615/549063	12887P3-US-PCT-w	US	Granted	13 Feb 2015	15/115403	30 Jan 2018	9877484
12984P3-US-PCTUSPending24 Feb 201615/54906312163P1-US-PRIUSGranted28 Apr 200009/55954216 Apr 2002637225212163P1-US-REX-2USGranted22 Apr 200590/00751416 Jun 20096372252C112163P1B-US-CIPUSGranted15 Apr 200210/12170618 Oct 2005695582112163P1B-US-CIP-2USGranted04 Apr 200310/40655723 Nov 2010783803212163P1B-US-CIP-3USGranted04 Apr 200310/40657426 Jul 2011798542012163P1B-US-CIP-4USGranted15 Apr 200310/41353006 Sep 2011801250412163P1B-US-CIP-5USGranted22 Jun 200511/15801226 Jul 2011798542112163P1B-US-CON-7USPending12 Sep 201615/26239512321P3-US-CNTUSPending28 Mar 201715/47178312583P3-US-CON-2USPending19 Apr 201615/13306212583P3-US-PCTUSPending21 Oct 201515/52075212958P3-US-PCTUSPending21 Oct 201515/520731	12959P3-US-PCT	US	Pending	30 Sep 2016	15/763920		
12163P1-US-PRIUSGranted28 Apr 200009/55954216 Apr 2002637225212163P1-US-REX-2USGranted22 Apr 200590/00751416 Jun 20096372252C112163P1B-US-CIPUSGranted15 Apr 200210/12170618 Oct 2005695582112163P1B-US-CIP-2USGranted04 Apr 200310/40655723 Nov 2010783803212163P1B-US-CIP-3USGranted04 Apr 200310/40657426 Jul 2011798542012163P1B-US-CIP-4USGranted15 Apr 200310/41353006 Sep 2011801250412163P1B-US-CIP-5USGranted22 Jun 200511/15801226 Jul 2011798542112163P1B-US-CN-7USPending12 Sep 201615/26239512321P3-US-CNTUSPending19 Apr 201615/13306212583P3-US-CON-2USPending19 Apr 201615/13306212583P3-US-PRIUSGranted04 Feb 201113/02124017 May 2016933947812957P3-US-PCTUSPending21 Oct 201515/52075212958P3-US-PCTUSPending21 Oct 201515/520731	12566P3-US-PRI	US	Granted	23 Jun 1999	09/338423	07 Nov 2000	6143285
12163P1-US-REX-2USGranted22 Apr 200590/00751416 Jun 20096372252C112163P1B-US-CIPUSGranted15 Apr 200210/12170618 Oct 2005695582112163P1B-US-CIP-2USGranted04 Apr 200310/40655723 Nov 2010783803212163P1B-US-CIP-3USGranted04 Apr 200310/40657426 Jul 2011798542012163P1B-US-CIP-4USGranted15 Apr 200310/41353006 Sep 2011801250412163P1B-US-CIP-5USGranted22 Jun 200511/15801226 Jul 2011798542112163P1B-US-CON-7USPending12 Sep 201615/26239512321P3-US-CNTUSPending19 Apr 201615/13306212583P3-US-PCTUSGranted04 Feb 201113/02124017 May 2016933947812958P3-US-PCTUSPending21 Oct 201515/520752	12984P3-US-PCT	US	Pending	24 Feb 2016	15/549063		
12163P1B-US-CIPUSGranted15 Apr 200210/12170618 Oct 2005695582112163P1B-US-CIP-2USGranted04 Apr 200310/40655723 Nov 2010783803212163P1B-US-CIP-3USGranted04 Apr 200310/40657426 Jul 2011798542012163P1B-US-CIP-4USGranted15 Apr 200310/41353006 Sep 2011801250412163P1B-US-CIP-5USGranted22 Jun 200511/15801226 Jul 2011798542112163P1B-US-CON-7USPending12 Sep 201615/26239512321P3-US-CNTUSPending19 Apr 201615/13306212583P3-US-CON-2USPending04 Feb 201113/02124017 May 2016933947812957P3-US-PCTUSPending21 Oct 201515/52075212958P3-US-PCTUSPending21 Oct 201515/520731	12163P1-US-PRI	US	Granted	28 Apr 2000	09/559542	16 Apr 2002	6372252
12163P1B-US-CIP-2 US Granted 04 Apr 2003 10/406557 23 Nov 2010 7838032 12163P1B-US-CIP-3 US Granted 04 Apr 2003 10/406574 26 Jul 2011 7985420 12163P1B-US-CIP-4 US Granted 15 Apr 2003 10/413530 06 Sep 2011 8012504 12163P1B-US-CIP-5 US Granted 22 Jun 2005 11/158012 26 Jul 2011 7985421 12163P1B-US-CIP-5 US Granted 22 Jun 2005 11/158012 26 Jul 2011 7985421 12163P1B-US-CON-7 US Pending 12 Sep 2016 15/262395	12163P1-US-REX-2	US	Granted	22 Apr 2005	90/007514	16 Jun 2009	6372252C1
12163P1B-US-CIP-3 US Granted 04 Apr 2003 10/406574 26 Jul 2011 7985420 12163P1B-US-CIP-4 US Granted 15 Apr 2003 10/413530 06 Sep 2011 8012504 12163P1B-US-CIP-5 US Granted 22 Jun 2005 11/158012 26 Jul 2011 7985421 12163P1B-US-CON-7 US Granted 22 Jun 2005 11/158012 26 Jul 2011 7985421 12163P1B-US-CON-7 US Pending 12 Sep 2016 15/262395 12321P3-US-CNT US Pending 28 Mar 2017 15/471783 12583P3-US-CON-2 US Pending 19 Apr 2016 15/133062 12583P3-US-PRI US Granted 04 Feb 2011 13/021240 17 May 2016 9339478 12957P3-US-PCT US Pending 21 Oct 2015 15/520752 12958P3-US-PCT US Pending 21 Oct 2015 15/520731	12163P1B-US-CIP	US	Granted	15 Apr 2002	10/121706	18 Oct 2005	6955821
12163P1B-US-CIP-4 US Granted 15 Apr 2003 10/413530 06 Sep 2011 8012504 12163P1B-US-CIP-5 US Granted 22 Jun 2005 11/158012 26 Jul 2011 7985421 12163P1B-US-CON-7 US Pending 12 Sep 2016 15/262395 12321P3-US-CNT US Pending 28 Mar 2017 15/471783 12583P3-US-CON-2 US Pending 19 Apr 2016 15/133062 12583P3-US-PRI US Granted 04 Feb 2011 13/021240 17 May 2016 9339478 12957P3-US-PCT US Pending 21 Oct 2015 15/520752 12958P3-US-PCT US Pending 21 Oct 2015 15/520731	12163P1B-US-CIP-2	US	Granted	04 Apr 2003	10/406557	23 Nov 2010	7838032
12163P1B-US-CIP-5 US Granted 22 Jun 2005 11/158012 26 Jul 2011 7985421 12163P1B-US-CON-7 US Pending 12 Sep 2016 15/262395 12321P3-US-CNT US Pending 28 Mar 2017 15/471783 12583P3-US-CON-2 US Pending 19 Apr 2016 15/133062 12583P3-US-PRI US Granted 04 Feb 2011 13/021240 17 May 2016 9339478 12957P3-US-PCT US Pending 21 Oct 2015 15/520752 12958P3-US-PCT US Pending 21 Oct 2015 15/520731	12163P1B-US-CIP-3	US	Granted	04 Apr 2003	10/406574	26 Jul 2011	7985420
12163P1B-US-CON-7 US Pending 12 Sep 2016 15/262395 Image: Constant of the system 12321P3-US-CNT US Pending 28 Mar 2017 15/471783 Image: Constant of the system Image: Constant of the system	12163P1B-US-CIP-4	US	Granted	15 Apr 2003	10/413530	06 Sep 2011	8012504
I2321P3-US-CNT US Pending 28 Mar 2017 15/471783 12583P3-US-CON-2 US Pending 19 Apr 2016 15/133062 12583P3-US-PRI US Granted 04 Feb 2011 13/021240 17 May 2016 9339478 12957P3-US-PCT US Pending 21 Oct 2015 15/520752 12958P3-US-PCT	12163P1B-US-CIP-5	US	Granted	22 Jun 2005	11/158012	26 Jul 2011	7985421
12583P3-US-CON-2 US Pending 19 Apr 2016 15/133062 12583P3-US-PRI US Granted 04 Feb 2011 13/021240 17 May 2016 9339478 12957P3-US-PCT US Pending 21 Oct 2015 15/520752 12958P3-US-PCT US Pending 21 Oct 2015 15/520731 1295277731 1295277731 12952777731 12952777772 1295277777777777777777777777777777777777	12163P1B-US-CON-7	US	Pending	12 Sep 2016	15/262395		
12583P3-US-PRI US Granted 04 Feb 2011 13/021240 17 May 2016 9339478 12957P3-US-PCT US Pending 21 Oct 2015 15/520752 15/520731 12958P3-US-PCT US Pending 21 Oct 2015 15/520731 15/520731	12321P3-US-CNT	US	Pending	28 Mar 2017	15/471783		
12957P3-US-PCT US Pending 21 Oct 2015 15/520752 12958P3-US-PCT US Pending 21 Oct 2015 15/520731	12583P3-US-CON-2	US	Pending	19 Apr 2016	15/133062		
12958P3-US-PCT US Pending 21 Oct 2015 15/520731	12583P3-US-PRI	US	Granted	04 Feb 2011	13/021240	17 May 2016	9339478
	12957P3-US-PCT	US	Pending	21 Oct 2015	15/520752		
13022P3-US-NP US Pending 11 Oct 2016 15/291061	12958P3-US-PCT	US	Pending	21 Oct 2015	15/520731		
	13022P3-US-NP	US	Pending	11 Oct 2016	15/291061		
						• • • • • • • • • •	

Schedule 2
Health Designs and Design Applications - Reckitt Benckiser LLC

Case reference	Country	Current Status	Filing Date	Application Number	Grant Date	Grant Number
12448D3-US-DES	US	Registered	25 Apr 2011		22 May 2012	
12448D3-US-DES-2	US	Registered	25 Apr 2011	29/390388	15 May 2012	D659453
12448D3-US-DES-3	US	Registered	25 Apr 2011	29/390389	08 May 2012	D658915
12828D3-US-PDS	US	Registered	10 Nov 2014		19 Jan 2016	D747791
12840D1-US-DCP-2	US	Registered	01 Jun 2015	1	27 Oct 2015	D741990
12840D1-US-DCP-3	US	Registered	21 Sep 2015	29/540070	10 May 2016	D755949
					11 4 2012	A2011/00E06

PATENT REEL: 049451 FRAME: 0066

Case reference	Country	Current Status	Filing Date	Application Number	Grant Date	Grant Number
1				11-1-1-12-14-14		

29/08/2018

2 of 2

PATENT REEL: 049451 FRAME: 0067

RECORDED: 06/12/2019